HCPCS Code Q5128: Injection, Ranibizumab-Eqrn (cimerli), biosimilar, 0.1 mg

HCPCS code Q5128 represents the administration service of the ranibizumab-eqrn, Cimerli, biosimilar 0.1 mg via intravitreal injection, a treatment intended for retinal diseases. This procedure is typically performed in an office or clinical setting by an MD or qualified healthcare provider.

Yes, the Cimerli biosimilar is FDA-approved. Providers should review CMS documentation and payer-specific access criteria, including billing dates and modifier usage, to ensure proper reimbursement.

Accurate coding requires documenting injection administration details, linked to the FDA-approved label and service dates. Use ASP (Average Sales Price) tables and CMS review resources for pricing and claims. Proper documentation facilitates access to reimbursement and adherence to regulatory requirements.